Bank of New York Mellon Corp Has $320,000 Stock Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA)

Bank of New York Mellon Corp reduced its holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) by 10.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 141,148 shares of the company’s stock after selling 16,945 shares during the quarter. Bank of New York Mellon Corp’s holdings in Cabaletta Bio were worth $320,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. HealthInvest Partners AB raised its position in Cabaletta Bio by 46.8% during the 4th quarter. HealthInvest Partners AB now owns 247,454 shares of the company’s stock worth $554,000 after purchasing an additional 78,932 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Cabaletta Bio by 23.3% in the fourth quarter. SG Americas Securities LLC now owns 43,259 shares of the company’s stock worth $98,000 after acquiring an additional 8,161 shares during the period. Avanza Fonder AB acquired a new position in shares of Cabaletta Bio in the fourth quarter worth approximately $40,000. Barclays PLC boosted its holdings in Cabaletta Bio by 48.2% in the third quarter. Barclays PLC now owns 61,130 shares of the company’s stock valued at $288,000 after acquiring an additional 19,891 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Cabaletta Bio by 12.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,094,644 shares of the company’s stock valued at $5,168,000 after purchasing an additional 124,071 shares during the period.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on CABA shares. TD Cowen raised shares of Cabaletta Bio to a “strong-buy” rating in a research note on Friday, November 29th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Cabaletta Bio in a research report on Tuesday, February 18th. Evercore ISI lowered Cabaletta Bio from an “outperform” rating to an “inline” rating and lowered their price objective for the stock from $15.00 to $6.00 in a research report on Friday, December 20th. Finally, Wells Fargo & Company lowered Cabaletta Bio from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $12.00 to $6.00 in a research report on Thursday, December 19th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $22.71.

Cabaletta Bio Stock Down 3.7 %

NASDAQ CABA opened at $1.55 on Friday. Cabaletta Bio, Inc. has a 52 week low of $1.45 and a 52 week high of $19.04. The business has a 50 day moving average price of $2.11 and a 200-day moving average price of $2.99. The company has a market cap of $75.76 million, a price-to-earnings ratio of -0.72 and a beta of 2.58.

Cabaletta Bio Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.